Published in Vaccine Weekly, August 31st, 2005
The SFDA issued a new drug certificate for Anflu in March, 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27 (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested the production equipment in the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have 3 GMP...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly